COVID vaccine

Booster Shots and Omicron: Side Effects, Eligibility and More

NBCUniversal Media, LLC

The omicron variant has led to a heightened push for booster shots around the country, with more ages becoming eligible and some groups now able to get their extra dose sooner than others.

Across Illinois, booster shot clinics have been sprouting up in recent weeks, including in several Chicago-area suburbs over the weekend. Mass vaccination sites are reopening in a number of Cook County suburbs this week, offering booster shots as well as initial doses.

But what do we know about booster shot efficacy, side effects and more, particularly surrounding the omicron variant?

Here's what we know so far:

Who is eligible for a booster shot?

The U.S. is urging that everyone 12 and older get a COVID-19 booster as soon as they're eligible, to help fight back the hugely contagious omicron mutant that's ripping through the country.

Boosters already were encouraged for all Americans 16 and older, but Wednesday the Centers for Disease Control and Prevention endorsed an extra Pfizer shot for younger teens — those 12 to 15 — and strengthened its recommendation that 16- and 17-year-olds get it, too.

The CDC is also recommending that children between the ages of 5 and 11 that are moderately or severely immunocompromised should get a third dose of the COVID vaccine 28 days after their second dose.

The vaccine made by Pfizer and its partner BioNTech is the only U.S. option for children of any age.

New U.S. guidelines say anyone who received two Pfizer or Moderna vaccinations and is eligible for a booster can get it five months after their last shot, rather than the six months previously recommended.

The Johnson & Johnson booster interval is two months.

The Illinois Department of Public Health announced earlier this month that it would adopt the CDC's latest recommendation for those aged 12-15 years to get a booster dose five months after receiving the second dose.

“We know that COVID-19 vaccine booster doses can help provide ongoing protection against the Omicron variant,” IDPH Director Dr. Ngozi Ezike said in a statement.  “Following the CDC’s recommendation, booster doses are encouraged for those aged 12-15 years who received their second dose of Pfizer-BioNTech vaccine five months ago.”

Chicago's health department followed suit.

"The Chicago Department of Public Health supports these decisions and encourages all eligible Chicagoans, age 12 and up, to get their booster dose now – no matter the type of COVID-19 vaccine they originally received," the Chicago Department of Public Health said in a release.

Does Pfizer's booster shot protect against omicron?

Pfizer said last month that a booster dose of its COVID-19 vaccine may offer important protection against the new omicron variant even though the initial two doses appear significantly less effective.

Pfizer and its partner BioNTech said that while two doses may not be protective enough to prevent infection, lab tests showed a booster increased by 25-fold people's levels of virus-fighting antibodies.

Blood samples taken a month after a booster showed people harbored levels of omicron-neutralizing antibodies that were similar to amounts proven protective against earlier variants after two doses.

Similarly, FDA vaccine chief Dr. Peter Marks said in a statement that agency made its decision to recommend extra doses for younger people because a booster “may help provide better protection against both the delta and omicron variants,” especially as omicron is “slightly more resistant” to the vaccine-induced antibodies that help fend off infection.

Real-world data from Israel tracked more than 6,300 12- to 15-year-olds who got a booster there at least five months after their second Pfizer dose and found no serious safety concerns, the FDA said.

Likewise, the FDA said even more data from Israel showed no problems with giving anyone eligible for a Pfizer booster that extra dose a month sooner than the six months that until now has been U.S. policy.

Still, the CDC's independent scientific advisers wrestled with whether a booster should be an option for younger teens, who tend not to get as sick from COVID-19 as adults, or more strongly recommended.

Giving teens a booster for a temporary jump in protection against infections is like playing whack-a-mole, cautioned CDC adviser Dr. Sarah Long of Drexel University. But she said the extra shot was worth it to help push back the omicron mutant and shield kids from the missed school and other problems that come with even a very mild case of COVID-19.

More important, if a child with a mild infection spreads it to a more vulnerable parent or grandparent who then dies, the impact “is absolutely crushing,” said panelist Dr. Camille Kotton of Massachusetts General Hospital.

“Let’s whack this one down,” agreed Dr. Jamie Loehr of Cayuga Family Medicine in Ithaca, New York.

The advisers saw U.S. data making clear that symptomatic COVID-19 cases and hospitalizations are between seven and 11 times higher in unvaccinated adolescents than vaccinated ones.

While children do tend to suffer less serious illness from COVID-19 than adults, child hospitalizations are rising during the omicron wave -- the vast majority of them unvaccinated.

During the public comment part of Wednesday's meeting, Dr. Julie Boom of Texas Children's Hospital said a booster recommendation for younger teens “cannot come soon enough.”

The chief safety question for adolescents is a rare side effect called myocarditis, a type of heart inflammation seen mostly in younger men and teen boys who get either the Pfizer or Moderna vaccines. The vast majority of cases are mild — far milder than the heart inflammation COVID-19 can cause — and they seem to peak in older teens, those 16 and 17.

The FDA decided a booster dose was as safe for the younger teens as the older ones based largely on data from 6,300 12- to 15-year-olds in Israel who got a Pfizer booster five months after their second dose. Israeli officials said Wednesday that they've seen two cases of mild myocarditis in this age group after giving more boosters, 40,000.

Earlier this week, FDA vaccine chief Dr. Peter Marks said the side effect occurs in about 1 in 10,000 men and boys ages 16 to 30 after their second shot. But he said a third dose appears less risky, by about a third, probably because more time has passed before the booster than between the first two shots.

Does Moderna's booster shot protect against omicron?

Moderna said its COVID-19 booster shot, which is only available for those 18 and older, does appear to provide protection against the omicron variant.

In an announcement last month, the drug company said preliminary data from lab testing found the version of its booster currently in use in the United States and elsewhere provided increased antibody levels to neutralize the virus. But it also found that a double dose of the booster shot provided a much greater increase in those levels.

The drug company said its currently FDA-approved 50 microgram booster was found to increase neutralizing antibody levels against omicron 37-fold compared to pre-boost levels. Meanwhile, it found that a 100 microgram booster dose gave an 83-fold increase in neutralizing antibody levels.

What about Johnson & Johnson?

Johnson & Johnson's booster shot, also only available for those 18 and older, provides high levels of protection against the omicron variant of COVID-19, according to data from a trial of healthcare workers in South Africa recently released.

Preliminary results from the Sisonke study, which have not been peer-reviewed, found that for people who had received one vaccine dose, the booster improved protection against hospitalization to 85 percent from 63 percent.

The study, carried out by the South African Medical Research Council compared 69,000 healthcare workers in South Africa to a group of unvaccinated South Africans.

The trial took place in November and December but participants were enrolled before the current wave now sweeping across the country, allowing researchers to "evaluate the effectiveness of the Company’s Covid-19 vaccine specifically as omicron became the dominant variant in the country," Johnson & Johnson said in a statement.

The Food and Drug Administration approved the Johnson & Johnson booster in October, but earlier this month the Centers for Disease Control and Prevention said people should get the Pfizer-BioNTech and Moderna boosters instead where possible, citing concerns over extremely rare blood clots.

Chicago's top doctor, Chicago Department of Public Health Commissioner Dr. Allison Arwady suggested those who got the J&J vaccine instead get a Moderna or Pfizer booster shot.

"It's especially important for people who got the J&J vaccine, if it's been just two months, please get a booster and have that booster be either Pfizer or Moderna," she said. "If you started with Pfizer or Moderna, your booster can be the same... but the most important thing is to get vaccinated and all three vaccines do remain available because we know that there are people who continue to prefer the J&J vaccine. I'm fine with that, just make sure you get a booster two months later."

What are the side effects with booster shots?

The CDC stated that side effects with the third shot "were similar to that of the two-dose series."

The most common symptoms include fatigue and pain at the injection site, but "most symptoms were mild to moderate."

As with previous doses of the vaccine, the CDC notes that, "serious side effects are rare, but may occur."

Do you need to wait to get your booster shot if you had COVID?

According to Arwady, people should wait 10 days after their positive test before getting their booster shot. This is in part due to isolation guidelines from the CDC.

"You should wait at least the 10 days, okay? During the time that you could be infectious," she said.

Arwady said that while those who recently recover from COVID do have antibodies, she still recommends getting a booster shot.

"Certainly if you've had a recent COVID infection, you've had your antibodies go up, but my recommendation to my staff, to my family, to everybody is particularly with the surge right now I would still recommending getting the booster," she said.

Should you get tested again before getting a booster shot after having COVID?

No, Arwady said, adding that guidance from the Centers for Disease Control and Prevention indicates people do not need to test out of quarantine or isolation and those who get a PCR test after COVID infection could test positive well after their active infection is over.

Is one vaccine better than the others?

Overall, Arwady said data currently shows both the Pfizer and Moderna vaccines are performing better than Johnson & Johnson's vaccine at preventing breakthrough infections, but all three protect against hospitalization and death.

"The CDC has changed its guidance to recommend as the first choice either Pfizer or Moderna," Arwady said. "I want to reassure people that the J&J vaccine continues to do a good job of protecting against those severe illnesses, but we are seeing more breakthroughs."

In a small preliminary study out of South Africa, where the omicron variant was first detected, scientists said the variant significantly reduces antibody protection generated by Pfizer and BioNTech's vaccine, although people who have recovered from the virus and received a booster shot will likely have more protection from severe disease.

The findings of the study were first released earlier this month.

While breakthrough infections are seemingly on the rise across all vaccines, cases in fully vaccinated and boosted individuals appear to be milder compared to unvaccinated patients, experts said.

"Hospitals, for the most part, are seeing people seriously ill with COVID, especially the unvaccinated," Arwady said. "The symptoms that we're seeing are not different with omicron than they were with delta, than they weren't with the original. It's just that where we are seeing more of is what we call breakthrough infections. So the vaccines continue to protect, but not as well against infection although they continue to protect beautifully against severe illness."

In Chicago and multiple Midwestern states, early cases of the omicron variant appeared in fully vaccinated residents, some of whom also received booster doses, though symptoms have so far remained mild in those populations.

"If [fully vaccinated people] get COVID, as opposed to getting seriously ill and having fevers for days and difficulty breathing, etc., they may only experience it as a mild illness," Arwady said. "They may only feel like they have a cold. That's good because they're not getting seriously sick. They're not threatening the healthcare system, but it's certainly of some concern because they do have the potential to transmit to others."

The unvaccinated, however, are experiencing similar symptoms to early on in the pandemic, Arwady said.

"People who are unvaccinated present in the same way: fevers, cough, chills, shortness of breath," she said.

Arwady's comments echo those of other medical experts who are watching omicron cases.

In New York, where cases continue to surge, an ER doctor who became known on social media during the pandemic for his documentation of the battle against COVID, reported breakthrough cases he has seen in those with booster shots experienced "mild" symptoms.

"By mild I mean mostly sore throat. Lots of sore throat," Craig Spencer wrote on Twitter. "Also some fatigue, maybe some muscle pain. No difficulty breathing. No shortness of breath. All a little uncomfortable, but fine."

Cases in people who were fully vaccinated with either Pfizer or Moderna's vaccine, but not boosted, remained mild, but slightly more intense.

"More fatigued. More fever. More coughing. A little more miserable overall. But no shortness of breath. No difficulty breathing," he wrote.

For those with Johnson & Johnson who were not boosted, he wrote the patients "felt horrible," with fevers, fatigue, coughs and shortness of breath, but did not require hospitalization or oxygen.

In the unvaccinated, however, the symptoms were more severe.

"Almost every single patient that I’ve taken care of that needed to be admitted for Covid has been unvaccinated," Spencer wrote. "Every one with profound shortness of breath. Every one whose oxygen dropped when they walked. Every one needing oxygen to breath regularly."

But despite reports of milder infections among the vaccinated, in Illinois, hospitalizations have been rising.

Pediatric hospitalizations are also rising across several states in the U.S., including in Illinois, an NBC News analysis of Department of Health and Human Services data found.

"No vaccine is perfect, for one thing," said Dr. Egon Ozer, who works in infectious diseases at Northwestern Medicine. "No vaccine is going to be a magic bullet. So, especially with so much virus that’s still circulating, there’s always potential that there’s going to be some breakthrough, that people are still going to be able to get some degree of the virus. That’s certainly been the case with delta, as well.”

Dr. Anthony Fauci said Wednesday that new data show booster shots of COVID-19 vaccines offer protection against the omicron variant and there is no current need to reformulate shots for variant-specific boosters.

At the same time, people who contract a breakthrough infection after receiving the COVID-19 vaccine may acquire a "super immunity" to the virus, researchers from the Oregon Health & Science University found.

A study, which was published in the Journal of the American Medical Association, revealed antibodies in blood samples of those with breakthrough infections were as much as 1,000% times more effective than those generated two weeks following the second dose of the Pfizer vaccine.

As part of the study, blood samples were collected from 52 people, all university employees who received the Pfizer vaccine. A total of 26 people were identified as having mild breakthrough infections following vaccination. Of those cases, 10 involved the highly-contagious delta variant, nine were non-delta and seven were unknown variants, according to the study.

NBC Chicago/Associated Press
Contact Us